FDA Confirms Departure of Ronald Farkas (SRPT)

September 14, 2016 10:24 AM EDT

Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.

The FDA, in an email to StreetInsider, confirmed that reviewer Ronald Farkas left the agency. Further details regarding the departure weren’t provided.

Rumors that Farkas took a job in the private sector surfaced after the market close on Tuesday, sending shares of DMD drug developer Sarepta Therapeutics (Nasdaq: SRPT) sharply higher in afterhours trading. Farkas was critical of Sarepta’s eteplirsen and his departure is viewed by some on Wall Street as a positive sign for approval.

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In

Related Categories

FDA, Hot FDA News, Rumors, Trader Talk

Add Your Comment